Humacyte Inc (HUMA) Stock Price, Quote & News

Company Profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 313 9633

Website: humacyte.com

Address:

2525 East North Carolina Highway 54, Durham, United States

tc_tc_tc Jan. 5 at 6:38 PM

$HUMA does anyone know whether Humacyte has a new agreement in place with Fresenius? Seems Fresenius have all rights for commercialization outside US for all SYMVESS etc. and HUMA gets transfer fees for supplying product. Fresenius have to do the marketing

0 · Reply

SqueezeDealer Jan. 5 at 6:05 PM

$BYD $SMLR $HUMA $NINE $ALMU m

0 · Reply

Michael_Krombopulos Jan. 5 at 5:56 PM

$HUMA holding over $1, watch for the attempt to manipulate it down before close. Need to not be consistently closing under $1

0 · Reply

Geauxtigers47 Jan. 5 at 5:03 PM

$HUMA keep climbing- I’ll cash out at 20$ lol

1 · Reply

goodguyvs Jan. 5 at 4:16 PM

$HUMA Make a run

0 · Reply

crowbaby333 Jan. 5 at 4:03 PM

$HUMA

1 · Reply

crowbaby333 Jan. 5 at 3:36 PM

$HUMA

1 · Reply

Ppbrain Jan. 5 at 3:28 PM

$HUMA so management waited nearly a year to submit application to israel to sell symvess ?? Am i getting this right?!!! Garbage

1 · Reply

Rodydiv Jan. 5 at 3:23 PM

$HUMA long term

1 · Reply

tman123451 Jan. 5 at 3:08 PM

$HUMA

0 · Reply

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

Dec 22, 2025, 8:00 AM EST - 14 days ago

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Dec 16, 2025, 8:00 AM EST - 20 days ago

Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital

Nov 20, 2025, 8:00 AM EST - 6 weeks ago

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Nov 13, 2025, 8:00 AM EST - 7 weeks ago

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Nov 12, 2025, 12:21 PM EST - 7 weeks ago

Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:00 AM EST - 7 weeks ago

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 8:00 AM EST - 2 months ago

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Nov 6, 2025, 8:00 AM EST - 2 months ago

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Oct 30, 2025, 8:00 AM EDT - 2 months ago

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Oct 7, 2025, 9:00 AM EDT - 3 months ago

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Oct 6, 2025, 8:00 AM EDT - 3 months ago

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Sep 29, 2025, 8:00 AM EDT - 3 months ago

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Sep 18, 2025, 7:00 AM EDT - 3 months ago

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Sep 15, 2025, 7:00 AM EDT - 4 months ago

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Aug 12, 2025, 1:20 PM EDT - 5 months ago

Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress

Aug 11, 2025, 10:00 AM EDT - 5 months ago

Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 7:00 AM EDT - 5 months ago

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 8:00 AM EDT - 5 months ago

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Jul 23, 2025, 8:00 AM EDT - 5 months ago

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Jul 8, 2025, 8:00 AM EDT - 6 months ago

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Jun 11, 2025, 9:05 AM EDT - 7 months ago

Humacyte: Revenue Ramp From Symvess Incoming

Jun 9, 2025, 8:00 AM EDT - 7 months ago

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Jun 2, 2025, 8:00 AM EDT - 7 months ago

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

May 19, 2025, 4:05 PM EDT - 8 months ago

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

May 13, 2025, 2:29 PM EDT - 8 months ago

Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 8 months ago

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025, 8:00 AM EDT - 8 months ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Mar 28, 2025, 1:48 PM EDT - 10 months ago

Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

Mar 28, 2025, 7:30 AM EDT - 10 months ago

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Mar 26, 2025, 8:00 AM EDT - 10 months ago

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Mar 25, 2025, 8:35 PM EDT - 10 months ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Mar 25, 2025, 4:01 PM EDT - 10 months ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Mar 10, 2025, 8:00 AM EDT - 10 months ago

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Mar 6, 2025, 8:00 AM EST - 10 months ago

Trestle Bio Announces Research Collaboration with Humacyte

Mar 3, 2025, 8:00 AM EST - 11 months ago

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Feb 27, 2025, 4:05 PM EST - 11 months ago

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 8:00 AM EST - 11 months ago

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Feb 26, 2025, 8:00 AM EST - 11 months ago

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Feb 20, 2025, 1:35 PM EST - 11 months ago

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Jan 21, 2025, 8:00 AM EST - 1 year ago

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

Jan 17, 2025, 10:30 AM EST - 1 year ago

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

tc_tc_tc Jan. 5 at 6:38 PM

0 · Reply

SqueezeDealer Jan. 5 at 6:05 PM

$BYD $SMLR $HUMA $NINE $ALMU m

0 · Reply

Michael_Krombopulos Jan. 5 at 5:56 PM

$HUMA holding over $1, watch for the attempt to manipulate it down before close. Need to not be consistently closing under $1

0 · Reply

Geauxtigers47 Jan. 5 at 5:03 PM

$HUMA keep climbing- I’ll cash out at 20$ lol

1 · Reply

goodguyvs Jan. 5 at 4:16 PM

$HUMA Make a run

0 · Reply

crowbaby333 Jan. 5 at 4:03 PM

$HUMA

1 · Reply

crowbaby333 Jan. 5 at 3:36 PM

$HUMA

1 · Reply

Ppbrain Jan. 5 at 3:28 PM

$HUMA so management waited nearly a year to submit application to israel to sell symvess ?? Am i getting this right?!!! Garbage

1 · Reply

Rodydiv Jan. 5 at 3:23 PM

$HUMA long term

1 · Reply

tman123451 Jan. 5 at 3:08 PM

$HUMA

0 · Reply

MarketPro Jan. 5 at 2:50 PM

$HUMA Buy Signal / Daily Chart

0 · Reply

Gnouss Jan. 5 at 2:12 PM

$HUMA 25$ reiterating easy money

3 · Reply

Rolf1968 Jan. 5 at 1:57 PM

$HUMA when life and limb is on the line Nobody wants to wait for conduit

1 · Reply

Fred_Sigma_Invest Jan. 5 at 1:54 PM

$HUMA https://stocks.apple.com/Alvf74ARqSJmaLLXAcd2HNA

1 · Reply

DARKP00L Jan. 5 at 1:44 PM

$HUMA 08:36 on Jan. 05 2026 D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target #tradeideas

1 · Reply

fatpie68 Jan. 5 at 1:36 PM

$HUMA “Israel represents just our first step in the global expansion of Symvess as we expect that our FDA approval enables expedited commercialization pathways in other territories, including those in Europe and the Middle East . We plan to report further expansion plans for Symvess based on the high level of interest we are receiving from healthcare providers in these regions.” - Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer https://elite.finviz.com/news/267026/humacyte-announces-planned-marketing-authorization-application-for-symvess-in-israel

2 · Reply

DipBuyInvester Jan. 5 at 1:35 PM

$ASBP MNTS as expected. $ASBP, $HUMA next!!

0 · Reply

DipBuyInvester Jan. 5 at 1:15 PM

$HUMA Early bird gets the worm.

0 · Reply

Runmaster83 Jan. 5 at 1:06 PM

$HUMA https://finance.yahoo.com/news/humacyte-announces-planned-marketing-authorization-130000789.html

0 · Reply

Eldredk Jan. 5 at 1:03 PM

$HUMA marketing auth in Israel news.

1 · Reply

fatpie68 Jan. 5 at 12:52 PM

No reason to sell $HUMA before the #SuperBowl - and I doubt any longs will want to sell afterward either.

0 · Reply

AndreaRR Jan. 5 at 10:01 AM

$HUMA

0 · Reply

Market Cap	182.59M
Revenue (ttm)	0.00
Net Income (ttm)	-148.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,121,337
Avg Vol	4,687,210
Day's Range	N/A - N/A
Shares Out	187.27M
Stochastic %K	26%
Beta	1.93
Analysts	Strong Sell
Price Target	$7.86